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Abstract
Intracranial germinoma sometimes present as bifocal germinoma, and whether bifocal ger-
minoma should be treated as a synchronous or disseminated disease remains unclear. This
study aimed to determine the optimal treatment modality for bifocal germinoma. Patients
with bifocal germinoma who received radiotherapy (RT) from March 1990 to August 2017
were included for analysis. A total of 21 patients were included. The median follow-up period
was 76.2 months (range, 6.2–305.4 months). There were 17 patients who received cranio-
spinal irradiation (CSI) with local RT; 3, whole ventricular RT (WVRT) with local RT; and 1,
local RT only. Three recurrences occurred (1 patient each among those who underwent
CSI, WVRT, and local RT). Recurrence in the patient who received CSI and who received
WVRT occurred in the right thalamus and right frontal convexity, respectively. Meanwhile,
the patient who received local RT showed not only a recurred lesion in the hypothalamus,
but also cerebrospinal fluid seeding. For this patient, salvage CSI was performed and com-
plete response was achieved after treatment. However, after 9 years and 6 months, he was
diagnosed with glioblastoma and expired. As for toxicity, although 17 patients showed
decrease in complete blood count levels during treatment, all patients recovered soon after
treatment completion. Our findings suggest that bifocal germinoma may be considered as a
disseminated disease when considering the patterns of failure according to RT fields. In
addition, patients who received CSI showed low acute toxicity rates. However, further stud-
ies are necessary to confirm these findings.
Introduction
Central nervous system (CNS) germ cell tumors are rare, accounting for only 0.5% of all pri-
mary brain and CNS tumors. Approximately 90% of these tumors develop in patients younger
than 20 years [1]. Germinoma is a type of germ cell tumor that shows good prognosis after
treatment. Intracranial germinomas present as bifocal germinoma in 6%-10% of patients,
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often synchronously in the pineal region and suprasellar area [1,2], and thus whether bifocal
germinoma should be treated as a synchronous or disseminated disease is still debated. Some
believe that bifocal germinoma is a synchronous local disease because of the excellent response
to treatment, while others say it is a disseminated disease due to the subsequent leptomenin-
geal metastasis in some patients [3]. Currently, bifocal germinoma is primarily considered a
disseminated disease in the United States, while it is considered a disseminated disease in
Europe [3,4].
At present, the preferred radiation treatment (RT) field for patients with disseminated ger-
minoma is cranio-spinal irradiation (CSI). However, although CSI has shown excellent results
for non-disseminated germinoma, the current recommended RT technique for non-dissemi-
nated germinoma is reduced field RT such as whole brain RT or whole ventricular RT
(WVRT) due to the toxicity of CSI [5–8]. Given that bifocal germinoma is yet to be established
clearly as a synchronous or disseminated disease, the optimal RT field for bifocal germinoma
also remains unclear.
This study aimed to determine whether bifocal germinoma is a synchronous or dissemi-
nated disease and identify the optimal treatment modality for such malignancy. Toward this




We retrospectively reviewed the medical records of patients with germinoma who received RT
between March 1990 and August 2017. Bifocal germinoma was defined as intracranial germi-
noma with another synchronous intracranial lesion (Fig 1). Patients with ventricular or spinal
dissemination or lesions arising in the ventricles were excluded.
The study was approved by the Institutional Review Board (IRB No. 4-2018-1170). The
informed consent was waived for this retrospective study.
Radiotherapy fields
Three types of field were used for RT, namely, local RT, WVRT, and CSI, and these included
the germinoma lesions, the whole ventricle, and the whole craniospinal axis, respectively. The
RT field was decided upon the physician’s preferences.
Treatment outcomes and statistical analysis
Patient, tumor, and treatment characteristics; treatment outcomes; and recurrence character-
istics were retrospectively reviewed. Acute toxicity events were thoroughly reviewed retro-
spectively and graded following the National Cancer Institute Common Terminology Criteria
for Adverse Events (version 4.03). Complete blood count levels during RT and after RT were
also reviewed.
The cumulative probability of progression-free survival was calculated using the Kaplan-
Meier method and compared using log rank test. All analyses were performed using SPSS ver-
sion 23.0 (IBM Inc., Armonk, NY, USA).
Results
Patient characteristics
Of the 192 patients with germinoma who received RT, 21 patients with bifocal germinoma
were included in the analysis. The median patient age was 18 years (range, 10–33 years), and
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most patients (86%) were male. The patient and tumor characteristics are shown in Table 1.
Three of 4 patients who did not receive CSI had received prior chemotherapy, which included
three regimens, namely, cisplatin/etoposide/bleomycin, cisplatin/etoposide, and carboplatin/
etoposide/cyclophosphamide.
The most common tumor location was the pineal gland and suprasellar region. All patients
had presenting symptoms at diagnosis such as headache and blurred vision, with a median
symptom duration of 2 months (range, 1–36 months). A total of 17 patients (81%) showed
endocrine dysfunction, and 9 patients (43%) had hydrocephalus. Approximately 50% of the
patients (11 patients) received biopsy, and 1 patient underwent subtotal removal of the tumor.
This patient showed tumor bleeding and left side weakness and thus underwent decompres-
sion surgery. One patient who underwent biopsy showed non-diagnostic results, and thus a
total of 11 patients were pathologically confirmed with germinoma. The median alpha-feto-
protein (AFP) and total human chorionic gonadotropin (ThCG) at diagnosis were 2.39 ng/mL
(range, 0.00–5.23 ng/mL) and 4.00 mIU/mL (range, 0.10–356.40 mIU/mL), respectively.
Patients with elevated hCG were all pathologically diagnosed with germinoma. Patients who
were difficult to perform biopsy due to tumor location were clinically diagnosed with neuro-
imaging studies and trial RT. Spinal magnetic resonance imaging (MRI) was performed in 12
patients (57%), and CSF cytology was checked in 9 patients (43%) to rule out seeding
metastases.
Analysis of treatment outcomes
The treatment characteristics are shown in Table 2. The largest RT field of each patient was
local field RT only for 1 patient, WVRT for 3 patients, and CSI for 17 patients. Except 1 patient
who received only local RT after systemic chemotherapy (patient No. 4), all patients were
treated with local RT plus WVRT or CSI. The RT doses according to the RT field are as
Fig 1. A case of bifocal germinoma at diagnosis. (a) Suprasellar lesion (white arrow) on MRI T1 gadolinium axial image. (b) Pineal lesion
(white arrow) on MRI T1 gadolinium axial image. (c) Bifocal lesions (white arrows) on MRI T1 gadolinium sagittal image. (d) Suprasellar lesion
(white arrow) on MRI T1 gadolinium coronal image; E) Pineal lesion (white arrow) on MRI T1 gadolinium coronal image.
https://doi.org/10.1371/journal.pone.0223481.g001
Treatment outcomes based on radiation therapy fields for bifocal germinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0223481 October 3, 2019 3 / 11
follows. For WVRT, a median total dose of 20 Gy (range, 18–20 Gy) with a fractional dose of 2
Gy; for whole-brain RT (WBRT), a median total dose of 18 Gy with a fractional dose of 1.8 Gy;
for CSI, a median total dose of 19.5 Gy (range, 18–34.2 Gy) with a fractional dose of 1.5 or 1.8
Gy. The median local boost RT dose was 18 Gy (range, 7.5–21.6 Gy) with a median fractional
dose of 1.8 Gy (range, 1.5–2.0 Gy). Six patients received trial RT. During RT, 8 patients (38%)
had to rest with a median period of 4 days (range, 2–18 days) due to leukopenia (n = 3), MRI
checking and replanning for trial RT (n = 4 patients), and equipment failure (n = 1).
Table 1. Patient and tumor characteristics. Patient and tumor characteristics of 21 patients.












1 F Pineal gland,
suprasellar
HA, blurred vision 36 DI + - - Negative




1 DI - - - Negative
3 M Pineal gland,
suprasellar
HA 1 + - - -




3 DI - - Negative Negative
5 F Thalamus, pituitary
stalk
Lt. hemiparesis 12 Panhypotituitarism - Germinoma - -
6 M Pineal gland,
suprasellar
HA, N, V 1 + - - -




0.5 DI - - - -
8 M Pineal gland,
suprasellar
Polydipsia, polyuria 8 DI - Germinoma - -
9 M Pineal gland,
hypothalamus
HA, V, polyuria 1 DI - - - -
10 M Pineal gland,
pituitary stalk
Polydipsia, polyuria 3 DI - - Negative -
11 M Basal ganglia,
hypothalamus
HA, Lt. arm weakness 1 - Germinoma Negative -
12 M Pineal gland,
pituitary stalk
Polydipsia, polyuria 4 DI - - - -
13 M Pineal gland,
hypothalamus
Polydipsia, polyuria 6 DI - Germinoma Negative -





3 DI - Germinoma Negative -
16 M Pineal gland,
suprasellar
HA 1 Panhypotituitarism + - Negative Negative
17 M Pineal gland,
suprasellar
HA, blurred vision 1 Panhypotituitarism + Germinoma Negative Negative
18 M Pineal gland,
suprasellar
Polydipsia, polyuria 5 DI - Germinoma Negative Negative
19 M Pineal gland,
suprasellar
Vision difficulty 4 Panhypotituitarism + Germinoma Negative Negative
20 M Pineal gland,
hypothalamus
HA, N, V, seizure 1 + Germinoma Negative Negative




1 DI + Germinoma Negative Negative
Abbreviations: F, female; M, male; HA, headache; N, nausea; V, vomiting; DI, diabetes insipidus; CSF, cerebrospinal fluid.
https://doi.org/10.1371/journal.pone.0223481.t001
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Chemotherapy was performed in 6 patients before RT. After chemotherapy, response evalu-
ation before the start of RT showed 3 complete response (CR) and 3 partial response (PR). Out
of the 3 patients who showed CR, 1 patient received local RT, 1 patient received WVRT, and
the last patient received CSI. As for those who showed PR, 1 patient received WVRT and the
other 2 patients received CSI.
During RT, 5 patients experienced grade 2 nausea. During RT, 3 and 1 patients developed
grade 2 and 3 anemia, respectively. In addition, 6 and 11 patients experienced grade 2 and 3
white blood cell decrease, and 5 and 3 patients experienced grade 2 and 3 neutrophil count
decrease, respectively. Grade 2 and 3 platelet count decrease was observed in 3 and 2 patients,
respectively. Although many patients experienced hematologic toxicities during RT, the CBC
levels of all patients were recovered soon after RT completion.
Posttreatment recurrence
In total, 3 recurrences occurred after RT. The recurrence rates according to the RT field are
shown in Table 3. Patients who received CSI showed the lowest recurrence rate, although the
difference was not statistically significant (p = 0.08). Recurrence characteristics and salvage
treatment of the patients who developed recurrence are shown in Table 4.
Recurrences occurred in those who received CSI, WVRT, and local field RT. The first
recurrence case occurred in the CSI group (1/17). This patient initially showed bifocal germi-
noma at the thalamus and pituitary stalk, and the lesion was pathologically confirmed. She
received CSI 19.5 Gy with local RT 19.8 Gy and developed recurrence 80 months after RT at
Table 2. Treatment characteristics. Treatment characteristics including chemotherapy regimen and radiotherapy schedule.
No Chemotherapy Response after CTx Recur
1 - CSI CSI 19.5 Gy+WB 18 Gy+Local 7.5 Gy -
2 - CSI CSI 19.5 Gy+WB 18 Gy+Local 12 Gy -
3 - CSI CSI 34.2 Gy+Local 20 Gy -
4 DDP/Etoposide/Bleomycin #4 CR Local field RT Local 19.8 Gy Yes
5 - CSI CSI 19.5 Gy+Local 19.8 Gy Yes
6 - CSI CSI 19.5 Gy+Local 19.8 Gy -
7 DDP/Etoposide #2 CR CSI CSI 19.5 Gy+Local 19.8 Gy -
8 - CSI CSI 19.5 Gy+Local 19.8 Gy -
9 DDP/Etoposide #4 PR CSI CSI 24.6 Gy+Local 16.2 Gy -
10 - CSI CSI 19.5 Gy+Local 19.8 Gy -
11 Carboplatin/Etoposide/Cyclophosphamide #6 PR CSI CSI 19.5 Gy+Local 19.8 Gy -
12 - CSI CSI 24 Gy+Local 16.2 Gy -
13 Carboplatin/Etoposide/Cyclophosphamide #6 CR WVRT WV 19.8 Gy+Local 10.8 Gy -
14 - CSI CSI 24 Gy+Local 21.6 Gy -
15 Carboplatin/Etoposide/Cyclophosphamide #4 PR WVRT WV 19.8 Gy+Local 10.8 Gy -
16 - CSI CSI 19.5 Gy+Local 16 Gy -
17 - CSI CSI 19.5 Gy+Local 16 Gy -
18 - CSI CSI 19.5 Gy+Local 16 Gy -
19 - CSI CSI 18 Gy+Local 18 Gy -
20 - WVRT WV 18 Gy+Local 18 Gy Yes
21 - CSI CSI 18 Gy+Local 18 Gy -
Abbreviations: CTx, chemotherapy; CR, complete response; PR, partial response; CSI, cranio-spinal irradiation; RT, radiotherapy; WVRT, whole ventricle radiotherapy;
WB, whole brain.
https://doi.org/10.1371/journal.pone.0223481.t002
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the right thalamus. After recurrence, the patient moved to another hospital and is still alive.
The second case occurred in the WVRT group (1/3 patients). The patient was pathologically
diagnosed with bifocal germinoma at the pineal gland and hypothalamus and received WVRT
18 Gy and local RT 18 Gy without prior chemotherapy. At 8.9 months post-RT, recurrence
occurred at the right frontal convexity, outside the RT field. On MRI, the recurred tumor had
a possibility of both recurrence of germinoma and meningioma. Thus, gross total tumor resec-
tion was performed, and the lesion was pathologically proven as recurred germinoma. Cur-
rently, the patient is alive, is on chemotherapy, and is indicated for RT after the chemotherapy.
The last patient who developed recurrence was the patient who received local RT only follow-
ing systemic chemotherapy. He was diagnosed with bifocal germinoma at the pineal gland and
pituitary stalk. Although this was not pathologically confirmed, the initial serum AFP was <5
ng/mL; ThCG,<5 mIU/mL; CSF AFP, 0.6 ng/mL; and beta hCG, <5 mIU/mL. Moreover, he
did not show any evidence of seeding on both spinal MRI and CSF cytology. He received che-
motherapy and showed CR prior to local RT 19.8 Gy. This patient showed recurrence at the
hypothalamus and also CSF seeding at 25.9 months post-RT. He was treated with salvage CSI
27 Gy (brain: 30 Gy) + local RT 10.5 Gy. After salvage RT, the patient showed CR but was diag-
nosed with glioblastoma after 9 years and 6 months. This patient expired due to glioblastoma
and was the only patient who expired out of the 21 patients. In addition, analysis of progres-
sion-free survival for the CSI group (n = 17) and local RT/WVRT group (n = 4) showed that
the CSI group tended to show better progression-free survival than the local RT/WVRT group,
although the difference was not statistically significant (p = 0.204; Fig 2).
Discussion
Intracranial germinoma is known to be highly radiosensitive and has shown excellent treat-
ment results. The standard treatment strategy for localized germinoma was a higher dose to
Table 3. Recurrences according to RT field. Recurrences according to cranio-spinal irradiation, whole ventricular
radiotherapy and local field radiotherapy.
Recur
No (n = 18) Yes (n = 3)
n (%) n (%) p
CSI (n = 17) 16 (94.1) 1 (5.9) 0.08
WVRT (n = 3) 2 (66.7) 1 (33.3)
Local field (n = 1) 0 (0.0) 1 (100.0)
Abbreviations: CSI, cranio-spinal irradiation; WVRT, whole ventricular radiotherapy
https://doi.org/10.1371/journal.pone.0223481.t003
Table 4. Recurrence characteristics and salvage treatment of patients with recurrence. Treatment and recurrence characteristics, salvage treatment and survival of
patients with recurrence.
No Chemotherapy RT field Recur at post-
RT (mo)







Salvage CSI 27 Gy (brain 30Gy)
+ local 10.5 Gy
CR, but diagnosed with
glioblastoma after 9Y6M
Dead
5 - CSI 80 Rt. Thalamus Follow up loss - Alive
20 - WVRT 8.9 Rt. Frontal convexity Tumor removal + on
chemotherapy
- Alive
Abbreviations: RT, radiotherapy; CSI, cranio-spinal irradiation; WVRT, whole ventricular radiotherapy; CSF, cerebrospinal fluid; Rt, right; CR, complete response
https://doi.org/10.1371/journal.pone.0223481.t004
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the neuraxis and primary tumor using CSI and local RT [9]. However, long-term RT-induced
toxicities were also observed although the survival rate improved to over 90%. Thereafter,
many investigators have been interested in reduced RT volume and dose [5,10]. Recently, sev-
eral studies have demonstrated that RT with reduced volume such as WVRT or WBRT showed
excellent treatment outcome without severe long-term toxicity. Thus, reduced-volume RT is
currently considered as the standard RT strategy for germinoma [11–13]. Meanwhile, CSI
remains the standard RT field for disseminated germinoma. However, in cases of bifocal ger-
minoma, there is no consensus on whether it should be treated as a synchronous disease or
disseminated disease and thus, the optimal RT field remains unclear.
Since bifocal germinoma is rare, only cases reports and few retrospective studies exist [14–
19]. Previous reports suggested that bifocal germinoma is a localized disease. Huang et al.
Fig 2. Progression-free survival according to the treatment field. Cranio-spinal irradiation tended to show better
progression-free survival, although not statistically significant (p = 0.204)).
https://doi.org/10.1371/journal.pone.0223481.g002
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reported 7 patients with bifocal germinoma who received WVRT of 30 Gy without chemother-
apy without any recurrences [19]. Another retrospective study from Canada reported no
recurrences in 6 patients with bifocal germinoma who received chemotherapy and WVRT
[17]. However, some studies reported contradicting results. Ogawa et al. retrospectively stud-
ied 165 patients with no evidence of spinal metastases who were treated with cranial RT with-
out spinal irradiation. Of these, 18 patients had bifocal tumor and 3 of the 18 patients had
spinal recurrence after initial treatment [20]. In another retrospective study, out of 55 patients
with bifocal germinoma, there were no failures in those who received CSI, 2 spinal failures in
17 patients who received limited RT field without chemotherapy, and 1 spinal failure in 23
patients who received limited RT field with chemotherapy [18]. In addition, another recent
study from China reported no spinal recurrence in 23 patients treated with CSI, but 4 spinal
failures in 24 patients treated with WVI or WBRT, thus advocating the use of CSI in bifocal
germinoma patients [21].
In our study, the recurrence pattern of the patient who received local RT was not only intra-
cranial recurrence, but also CSF dissemination. Meanwhile, the patient who recurred locally
and who showed outfield intracranial recurrence received CSI and WVRT, respectively. Con-
sidering the pattern of failure in our study, bifocal germinoma seems to be a disseminating
entity. Phi et al. have reported that of the 23 patients with bifocal germ cell tumor, 47.8% had
tumor seeding at presentation, and tumor seeding was significantly associated with bifocal
lesions (p< 0.001) [22]. Thus, they concluded that bifocal lesions may result from the meta-
static spread of suprasellar or pineal lesions. Some researchers argued that local RT or WVRT
with or without chemotherapy is feasible as definitive treatment due to the high CR rate and
the effective salvage treatments after recurrence [17,19]. However, the patient who developed
recurrence who received local RT in our institution was salvaged successfully via CSI with
local RT. Thereafter, glioblastoma eventually developed, which may be considered a secondary
malignancy because the sum of the irradiated dose to primary lesion was high (60.3 Gy) [23].
We consider that successful initial treatment is important because patients with bifocal germi-
noma tend to be young and have a long life expectancy and would be less exposed to cytotoxic
treatment owing to successful initial treatment.
In addition, the location of the tumor may be a matter of concern for bifocal germinoma
patients. Germinomas are most commonly located in the pineal region, followed by suprasellar
region. Germinomas arising from basal ganglia and thalamus are rare and have atypical clini-
cal presentation compared to those located in pineal or suprasellar region. They show variable
radiologic findings, can cause atropic changes with neurologic deficits and the rate of treat-
ment failure is reported to be higher [24–26]. In this study, the location of the tumor of the
patient who recurred after local field RT was in the pineal gland and suprasellar area. As for
the other two recurred cases, one case which was located in the thalamus and pituitary stalk
recurred even with CSI, and the other case which was located in the hypothalamus and pineal
gland recurred in the brain parenchyme after WVRT. Thus, local field RT may be insufficient
for both bifocal germinomas located in the traditional areas and non-traditional areas.
As for toxicity, the acute toxicity rates were reasonable, and all patients recovered from
hematologic toxicity after RT completion, showing that RT can be a tolerable treatment for
bifocal germinoma patients. As for late toxicity, our study could not analyze neurocognitive
function or quality of life due to its retrospective nature. However, there have been previous
reports concerning this matter in patients with germinoma who received CSI. In germinoma
patients, late toxicity after RT is generally negligible [13]. Merchant et al. reported no signifi-
cant differences between pre- and post-RT full-scale, verbal, and performance IQ scores in 12
patients with germinoma who received CSI [27]. Another study reported a generally good
quality of life in 22 adult survivors of germinomas treated with CSI [28]. Previous studies
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reporting poor neurocognitive outcome refer to CSI in other types of brain tumor, which
shows different presentation compared to germinoma [29,30]. For example, patients with
medulloblastoma show lower age at diagnosis, receives more aggressive surgery, and presents
with more hydrocephalus, which increases the risk of neurocognitive damage [29,30]. Further-
more, the RT dose used for CSI in this study was mostly under 20 Gy, which is lower than in
other tumor types such as medulloblastoma [31]. The risk and severity of chronic toxicity is
increased with younger age and higher RT doses [32]. Asides from neurocognitive function,
concerns for the development of bones and soft tissue for young patients, especially younger
than the age of 10 years, can be raised [4]. Previous study reported that CSI administered at
the age of 8 years or younger was related to short stature [33]. In this study, there were no
patients younger than the age of 10 years. However, to treat younger bifocal patients, CSI by
proton beam therapy can be considered to lower the radiation dose to the spine [34]. Further-
more, although one may suggest that CSI may be overtreatment and that it is low cost-effec-
tive, low dose CSI and omitting chemotherapy would be the most favorable option if CSI is
regarded as a disseminated disease. Previously, the benefit of addition of chemotherapy was
not demonstrated in disseminated germinoma patients [35]. Overall, CSI seems to be a reason-
able treatment option for patients with bifocal germinoma in terms of both tumor control and
toxicity.
There are limitations to this study due to its retrospective nature, including the lack of data
for late toxicity. However, this study also has several strengths. First, the study included a rela-
tively large number of patients with bifocal germinoma despite its single-center design. More-
over, acute toxicity was thoroughly reviewed and reported.
Conclusions
Our findings suggest that bifocal germinoma may be considered as a disseminated disease
when considering the patterns of failure according to RT fields. In addition, patients who
received CSI showed low acute toxicity rates. However, further studies are necessary to con-
firm these findings.
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